In December 2005, 40-year-old John Danner was going to make his first presentation to the board of directors of Codon Devices, one-year-old biotech startup based in Cambridge, Massachusetts. A month later, as the CEO of the company, Danner was ready to put his strategic plan for the firm. The company was quick to seize a share of a billion dollars of DNA-synthesis market. Codon has several features to the company, its size and age: it is already generating revenues from a number of different types of customers for its genetic product and is capable of revolutionizing the look of fragmented DNA-synthesis market, he received extraordinary support from its oversized Scientific Advisory Board, he developed and provided a strong intellectual property portfolio, which creates high barriers to entry for any new market participants., and it was $ 13 million venture capital investment from Flagship Ventures, Khosla Ventures, Kleiner, Perkins, and other "hidden
by Joseph B. Lassiter, David Kiron Source: Harvard Business School 16 pages. Publication Date: May 18, 2006. Prod. #: 806198-PDF-ENG
Related Case Solutions & Analyses:
Cirque du Soleil–The High-Wire Act of Building Sustainable Partnerships
The Pepsi Refresh Project: Thirst for Change
Revenue-Recognition Problems in the Communications Equipment Industry
Cleveland Clinic Heart Center: Legacy of Excellence
The Battle Over the Clinton Health Care Proposal
Carrier and Tyler Refrigeration: An Acquisition for Growth
Hans Fritz at Novartis Thailand (D): The First 18 Months
Price Cap: The UKs Efforts to Regulate Regional Distribution Companies
CCBN.COM
Franco Bernabe at ENI (B)
